Quarterly ResultApr 29, 2026, 07:07 AM
AMRN Q1 Revenue +7% to $45.1M; Net Loss Narrows 33%
AI Summary
Amarin reported Q1 2026 total net revenue increased 7% to $45.1 million, driven by higher international sales and licensing revenue. The company significantly narrowed its net loss by 33% to $10.5 million and generated positive cash flow for the second consecutive quarter, reiterating its full-year positive cash flow expectation. The refined global business model, including the European partnership with Recordati, and updated industry guidelines supporting icosapent ethyl (IPE) contributed to the positive outlook.
Key Highlights
- Total Net Revenue increased 7% to $45.1 million in Q1 2026.
- Net Loss improved 33% to $(10.5) million, or $(0.03) per share.
- Operating Expenses decreased 31% to $29.1 million, excluding restructuring charges.
- Generated positive cash flow for the second consecutive quarter; expects full-year positive cash flow.
- Cash and investments rose to $307.8 million as of March 31, 2026.
- U.S. VASCEPA prescriptions rose 17% compared to Q1 2025.
- Licensing & Royalties revenue increased 84% to $1.8 million.
- $3.3 million in restructuring charges recognized in Q1 2026, with $39.6 million incurred to date.
Price Impact
More from AMRN